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Clinics and pathology 
Disease 
Chronic lymphoproliferative disorder (CLD) 
Phenotype/cell stem origin 
Disease affecting mature B-cells. 
Immunophenotypically, B-PLL is characterized by 
reactivity with pan B-cell markers CD19, CD20 and 
CD24.  
B-PLL cells are distinct from B-CLL cells in that 
they express bright surface immunoglobulin, 
unfrequently express CD5, fail to form rosettes with 
mouse erythrocytes and react strongly with FMC7.  
Expression of CD22 is often observed whereas 
CD23 is usually not expressed. 
Epidemiology 
Rare disease; slight male predominance with 
median age of 69 years. 
Clinics 
Patients often present with advanced stage disease.  
B-PLL is characterized by high white blood cell 
counts and splenomegaly without adenopathy. 
Bone marrow infiltration pattern is either diffuse or 
mixed.  
Blood data: elevated white blood cell counts with 
prolymphocytes representing more than 55% of the 
circulating lymphoid cells. 
Anemia and thrombocytopenia may be observed. 
Prognosis 
Evolution: this disease is always progressive. 
Prognosis: poor response to therapy is often 




Few studies focused on B-PLL; the use of B-cell 
mitogens might increase the detection rate of 
cytogenetic changes; the most frequent aberrations 
involve chromosomes 14, 6 and 1; 14q+ changes 
are the most commonly observed and are often the 
consequence of a translocation t(11;14)(q13;q32); 
structural abnormalities of chromosome 6 are 
primary or secondary; deletion 6q, as well as 
translocation t(6;12)(q15;p13) are described; 
structural aberrations of chromosome 1 involve 
both p and q arms; trisomy 12 represents a 
secondary change in this disease; finally, 
i(17)(q10), as well as telomeric associations have 
been reported; karyotypic evolution has been 
documented in some cases and seems to be 
associated with disease progression. 
Genes involved and 
proteins 
Note 
Little is known about underlying genetic 
mechanisms in B-PLL. 
Immunoglobulin gene rearrangements are always 
observed.  
BCL-1 gene is involved in some cases bearing 
t(11;14)(q13;q32), with breakpoints located 
centrometric to the major translocation cluster.  
Overall, abnormalities of P53 occur in 75% cases, 
representing the highest reported frequency in B-
cell malignancies.  
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No CDKNL-2 or RB1 gene involvement has been 
documented so far.  
C-MYC rearrangement has been described in PLL. 
To be noted 
Note 
T-cell prolymphocytic leukaemia also exists and 
account for 1/4 of cases of PLL. 
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